ClinicalTrials.gg
CompletedNCT01365117Updated Jun 14, 2012

Pharmacokinetic Study in Healthy Volunteers

A Phase 1 interventional study of Technosphere® Insulin Inhalation Powder and Technosphere® Insulin Inhalation Powder in Healthy Volunteers, sponsored by Mannkind Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-14.

Sponsored by Mannkind Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Phase 1 clinical trial to evaluate insulin exposure using different formulations of Technosphere Insulin Inhalation Powder using the Gen2 inhaler in healthy normal volunteers.

Read the detailed description

Phase 1, single-center, open-label, randomized, crossover clinical trial to evaluate insulin exposure using the 3 U/mg and 4 U/mg Technosphere Insulin Inhalation Powder formulations administered using the Gen2 inhaler in 31 healthy volunteers. Drop outs will be replaced. Each subject will undergo a screening visit and either 4 or 5 days of in clinic stay and dosing, depending on randomization schedule.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoking (within the last 6 months) men and women aged 18 to 45 years who are considered healthy
  • (BMI) \< 32 kg/m2
  • ≥ 80% of the Third National Health and Nutrition Examination Survey (NHANES III) predicted

Exclusion criteria

Exclusion Criteria:

  • Pre-existing asthma or (COPD)
  • History of coronary artery disease, peripheral vascular disease, or congestive heart failure
  • Blood donation within the previous 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: Technosphere® Insulin Inhalation Powder

  • Experimental
    Cohort 2

    Drug: Technosphere® Insulin Inhalation Powder

Interventions

  • 15 subjects in a three-way crossover (three different doses of TI Inhalation Powder \[one 20 U, two 20 U and one 40 U cartridges)

    Also known as: Inhaled human insulin and Technosphere Powder

  • 16 subjects in a four-way crossover (four different doses of TI Inhalation Powder \[one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)\])

    Also known as: Inhaled human insulin and Technosphere Powder

06

What researchers measure

Primary outcomes

  1. The relative exposure (Cmax and AUC0-120) of insulin from TI Inhalation Powder as delivered

    Time frame: 0-120 minutes

Secondary outcomes

  1. Safety will be assessed by adverse events

    Time frame: 32 days

  2. Safety will be assessed by Spirometry (FEV1)

    Time frame: 32 Days

  3. Safety will be assessed by vital sign measurements

    Time frame: 32 Days

  4. Safety will be assessed by physical examination findings.

    Time frame: 32 Days

  5. Safety will be assessed by clinical laboratory test results.

    Time frame: 32 Days

07

Study locations

1 site
  • Celerion
    Neptune, New Jersey 07753, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Feb 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2011
First posted
Jun 3, 2011
Start
Jan 2011
Primary completionActual
Feb 2011
CompletionActual
Apr 2011
Last update
Jun 14, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01365117
Responsible party
Sponsor
First posted
Jun 3, 2011
Start date
Jan 2011
Primary completion
Feb 2011
Completion
Apr 2011
Last update
Jun 14, 2012

Study contacts

Sandra Connolly, M.D.
principal investigator · Celerion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion